Sophia Genetics SA SOPH.OQ, SOPH.O is expected to show a rise in quarterly revenue when it reports results on March 4 for the period ending December 31 2024
The Rolle Vaud-based company is expected to report a 3.9% increase in revenue to $17.72 million from $17.05 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Sophia Genetics SA is for a loss of 22 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Sophia Genetics SA is $6.00, above its last closing price of $3.60.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.24 | -0.23 | -0.28 | Missed | -21.7 |
Jun. 30 2024 | -0.28 | -0.28 | -0.23 | Beat | 18.6 |
Mar. 31 2024 | -0.27 | -0.27 | -0.21 | Beat | 23.2 |
Dec. 31 2023 | -0.25 | -0.27 | -0.37 | Missed | -37 |
Sep. 30 2023 | -0.33 | -0.32 | -0.21 | Beat | 35.1 |
Jun. 30 2023 | -0.30 | -0.31 | -0.33 | Missed | -7.7 |
Mar. 31 2023 | -0.31 | -0.32 | -0.31 | Beat | 2 |
Dec. 31 2022 | -0.36 | -0.36 | -0.22 | Beat | 39.2 |
This summary was machine generated February 28 at 13:54 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。